ArticleMolecular nutrition & food research2026
ω-3PUFAs Inhibit Gallbladder Cancer Through Enhancing STK31 Methylation.
Article in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- STK31 enhances gallbladder cancer development by modulating DNA replication machinery.The Journal of biological chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Gallbladder cancer (GBC) is an aggressive malignancy with limited treatment options. ω-3PUFAs have known anticancer activity, but their role in GBC remains unclear. The anti-GBC effects of ω-3PUFAs (DHA/EPA) were evaluated using in vitro assays and mouse xenograft models. Epigenetic changes were analyzed by RRBS, MSP, and MethyLight PCR. Downstream mechanisms were explored via proteomics, Co-IP, and Western blot. This study demonstrates that ω-3PUFAs suppress GBC progression by inducing promoter hypermethylation of STK31, which is an oncogene found in GBC by our previous study. MethyLight PCR revealed that ω-3PUFAs treatment significantly increased STK31 promoter methylation in GBC-SD cells from 34.1% ± 20.91% to 89.1% ± 13.11%. Moreover, STK31(DNMT1)/GSK3β pathway and COL4A1 (ITGB1) were particularly associated with ω-3PUFAs' inhibitory mechanisms to GBC. In vivo experimental results demonstrated that ω-3PUFAs significantly inhibited the growth of gallbladder cancer xenografts, with tumor growth inhibition rates of 38.6% for GBC-SD and 50.2% for NOZ at day 33, and effectively suppressed tumor cell metastasis in an intraperitoneal mouse model. This study provides first evidence that ω-3PUFAs target STK31 via epigenetic reprogramming, opening new avenues for dietary intervention and targeted therapy of GBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.